28 November 2023 in Cancer Epidemiology, Biomarkers & Prevention
Background: Cancer is becoming more of a chronic disease due to improvements in treatment and early detection for multiple cancer sites. To gain insight on increased life expectancy due to these improvements, we quantified trends in the loss in expectation of life (LEL) due to a cancer diagnosis for six cancer sites from 1975 through 2018. Methods: We focused on patients diagnosed with female breast cancer, chronic myeloid leukemia (CML), colon and rectum cancer, diffuse large B-cell lymphoma (DLBCL), lung cancer, or melanoma between 1975 and 2018 from nine Surveillance, Epidemiology, and End Results cancer registries. Life expectancies for patients with cancer ages 50+ were modeled using flexible parametric survival models. LEL was calculated as the difference between general population life expectancy and life expectancy for patients with cancer. Results: Over 2 million patients were diagnosed with one of the six cancers between 1975 and 2018. Large increases in life expectancy were observed between 1990 and 2010 for female breast, DLBCL, and CML. Patients with colon and rectum cancer and melanoma had more gradual improvements in life expectancy. Lung cancer LEL only began decreasing after 2005. Increases in life expectancy corresponded with decreases in LEL for patients with cancer. Conclusions: The reported gains in life expectancy largely correspond to progress in the screening, management, and treatment of these six cancers since 1975. Impact: LEL provides an important public health perspective on how improvements in treatment and early detection and their impacts on survival translate into changes in cancer patients’ life expectancy.
14 June 2025 in JNCI: Journal of the National Cancer Institute
Background: Improvements in outcomes among children and adolescents diagnosed with cancer are attributable to many factors, including clinical trials such as those administered through the Children’s Oncology Group (COG) as well as population-based resources such as the National Childhood Cancer Registry (NCCR). The objective of this study was to link COG trial data with the NCCR to evaluate overall enrollment patterns. Methods: Data were received from the NCCR and COG that were linked using an array of variables, then compared to evaluate enrollment patterns in COG studies from 2007 to 2018. Multivariable logistic regression was used to identify characteristics associated with not being enrolled in a COG study. Results: Among 134 696 NCCR patients with cancer, 51 062 matched with COG study enrollees. There were several differences in demographic and clinical characteristics between individuals enrolled and not enrolled in COG studies. Enrollment was higher among children aged from birth to 4 years compared with adolescents aged 15-19 years (53.7% vs 20.1%). Differences by race and ethnicity were also observed; for example, individuals who identified as non-Hispanic White were more likely to be enrolled than were individuals who identified as non-Hispanic Asian or Pacific Islander (38.8% vs 32.9%). In a multivariable logistic regression model, several characteristics were strongly associated with not being enrolled in a COG study, including age at diagnosis, year of diagnosis, race and ethnicity, and cancer type. Conclusion: Our results suggest that several groups are underrepresented in COG clinical trials. This information can help guide the prioritization of population groups for engagement in future studies.